Last reviewed · How we verify
Coagadex
At a glance
| Generic name | Coagadex |
|---|---|
| Also known as | Factor X |
| Sponsor | Bio Products Laboratory |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis (PHASE3)
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z (PHASE1)
- Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) (PHASE3)
- Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery (PHASE4)
- Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin (PHASE1)
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coagadex CI brief — competitive landscape report
- Coagadex updates RSS · CI watch RSS
- Bio Products Laboratory portfolio CI